Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827961 | 1.00 | NOS2 (0.41) | NOS2MAPTALDH1A1THRBNPC1 | |
| SCHEMBL5187606 | 1.00 | NOS2 (0.41) | NOS2MAPTALDH1A1THRBNPC1 | |
| SCHEMBL3236180 | 1.00 | NOS2 (0.41) | NOS2MAPTALDH1A1THRBNPC1 | |
| SCHEMBL3236172 | 1.00 | NOS2 (0.41) | NOS2MAPTALDH1A1THRBNPC1 | |
| SCHEMBL3236465 | 1.00 | NOS2 (0.41) | NOS2MAPTALDH1A1THRBNPC1 | |
| SCHEMBL828090 | 0.92 | ALDH1A1 (0.41) | MAPTALDH1A1NPC1MAOBRAB9A | |
| SCHEMBL828091 | 0.92 | ALDH1A1 (0.41) | MAPTALDH1A1NPC1MAOBRAB9A | |
| SCHEMBL3236485 | 0.92 | HSD11B1 (0.41) | MAPTHTTMAOB | |
| SCHEMBL3236845 | 0.92 | HSD11B1 (0.41) | MAPTHTTMAOB | |
| SCHEMBL3236500 | 0.92 | HSD11B1 (0.41) | MAPTHTTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689706-B1 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIV - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-11 | — | — | EP | claimed |
| EP-1896401-B1 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | UNIV TEMPLE (US) | 2013-04-10 | — | — | EP | claimed |
| US-7744889-B2 | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-06-29 | — | — | US | claimed |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-14 | — | — | US | claimed |
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | ONCONOVA THERAPEUTICS INC. | 2006-12-14 | — | — | US | claimed |
| EP-1689706-B1 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIV - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-1896401-B1 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | UNIV TEMPLE (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8143453-B2 | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-03-27 | — | — | US | disclosed |
| US-7744889-B2 | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-14 | — | — | US | disclosed |
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | ONCONOVA THERAPEUTICS INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | SULT1E1, GSTO1, CCNA1 | NOS2 1071/4885MAPT 4812/4885ALDH1A1 102/4885 |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | SULT2A1, SULT1A1, ARSA | NOS2 1088/4885MAPT 3643/4885ALDH1A1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.